GPCR SEC Filing News — Structure Therapeutics Inc.

Latest SEC filings for Structure Therapeutics Inc. (GPCR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-22.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, a…
Sector: Healthcare Industry: Biotechnology Market Cap: $1.6B CIK: 1888886
20
Total Filings
0
Bullish Classifications
0
Bearish Classifications
14
Insider Transactions
3
Material Events (8-K)
1
Periodic Reports
What you're looking at: Each item below is parsed from an actual SEC filing submitted by Structure Therapeutics Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.
GPCR Filing Activity Snapshot 2026-06-18 — 2026-09-22
Insider Transactions (Form 4)
0 buys vs 0 sells
Insider buying and selling activity is balanced in this period.
Largest Form 144 Filing
$1.71M
XICHEN LIN · 2026-06-25
35,512 shares · Form 144
Form 144 Notices
2
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 14 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 14 filings in this group are Form 4s for Structure Therapeutics Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 14 insider filings shown, the breakdown is 7 compensation award and 7 open-market sale. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×7
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Tax / Compensation Filing 2026-09-22

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Coll Crespo Blas (CHIEF MEDICAL OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 10,626 $11.67 $124.0K
C Derivative conversion 12,024 — —
C Derivative conversion derivative · American Depositary Shares 4,008 — —
S Open-market sale derivative · American Depositary Shares 4,008 $36.15 $144.9K
Filing: Form 4 (Insider Transaction) Insider: Coll Crespo Blas (CHIEF MEDICAL OFFICER) Shares: 22,650
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Tax / Compensation Filing 2026-09-02

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Lin Xichen (CHIEF SCIENTIFIC OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 17,817 $0.34 $6.1K
C Derivative conversion 17,817 — —
M Option exercise derivative · Share Option (right to buy) 17,817 — —
C Derivative conversion derivative · American Depositary Shares 5,939 — —
S Open-market sale derivative · American Depositary Shares 1,300 $45.86 $59.6K
S Open-market sale derivative · American Depositary Shares 4,539 $47.20 $214.3K
S Open-market sale derivative · American Depositary Shares 100 $47.83 $4.8K
Filing: Form 4 (Insider Transaction) Insider: Lin Xichen (CHIEF SCIENTIFIC OFFICER) Shares: 35,634
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Tax / Compensation Filing 2026-08-19

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Lin Xichen (CHIEF SCIENTIFIC OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 11,817 $0.34 $4.0K
C Derivative conversion 11,817 — —
M Option exercise derivative · Share Option (right to buy) 11,817 — —
C Derivative conversion derivative · American Depositary Shares 3,939 — —
S Open-market sale derivative · American Depositary Shares 3,020 $53.13 $160.5K
S Open-market sale derivative · American Depositary Shares 519 $54.20 $28.1K
S Open-market sale derivative · American Depositary Shares 400 $55.05 $22.0K
Filing: Form 4 (Insider Transaction) Insider: Lin Xichen (CHIEF SCIENTIFIC OFFICER) Shares: 23,634
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-08-07

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Berrios John Joseph (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 140,766 — —
A Compensation award derivative · Share option (right to buy) 174,612 — —
Filing: Form 4 (Insider Transaction) Insider: Berrios John Joseph (Chief Commercial Officer) Shares: 140,766
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Tax / Compensation Filing 2026-08-05

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Lin Xichen (CHIEF SCIENTIFIC OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 11,817 $0.34 $4.0K
C Derivative conversion 11,817 — —
M Option exercise derivative · Share Option (right to buy) 11,817 — —
C Derivative conversion derivative · American Depositary Shares 3,939 — —
S Open-market sale derivative · American Depositary Shares 3,100 $49.29 $152.8K
S Open-market sale derivative · American Depositary Shares 839 $50.03 $42.0K
Filing: Form 4 (Insider Transaction) Insider: Lin Xichen (CHIEF SCIENTIFIC OFFICER) Shares: 23,634
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Tax / Compensation Filing 2026-07-24

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

FMR LLC (10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale derivative · American Depositary Shares 1,367 $50.07 $68.4K
S Open-market sale derivative · American Depositary Shares 16,085 $50.07 $805.4K
Filing: Form 4 (Insider Transaction) Insider: FMR LLC (10% Owner)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Tax / Compensation Filing 2026-07-15

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Lin Xichen (CHIEF SCIENTIFIC OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 23,634 $0.34 $8.0K
C Derivative conversion 23,634 — —
M Option exercise derivative · Share Option (right to buy) 23,634 — —
C Derivative conversion derivative · American Depositary Shares 7,878 — —
S Open-market sale derivative · American Depositary Shares 6,278 $50.80 $318.9K
S Open-market sale derivative · American Depositary Shares 1,600 $51.71 $82.7K
Filing: Form 4 (Insider Transaction) Insider: Lin Xichen (CHIEF SCIENTIFIC OFFICER) Shares: 47,268
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Tax / Compensation Filing 2026-06-29

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Lin Xichen (CHIEF SCIENTIFIC OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 23,634 $0.34 $8.0K
C Derivative conversion 23,634 — —
M Option exercise derivative · Share Option (right to buy) 23,634 — —
C Derivative conversion derivative · American Depositary Shares 7,878 — —
S Open-market sale derivative · American Depositary Shares 7,878 $49.08 $386.6K
Filing: Form 4 (Insider Transaction) Insider: Lin Xichen (CHIEF SCIENTIFIC OFFICER) Shares: 47,268
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Russell Angus C. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Share Option (right to buy) 39,453 — —
Filing: Form 4 (Insider Transaction) Insider: Russell Angus C. (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

LOVE TED W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Share Option (right to buy) 39,453 — —
Filing: Form 4 (Insider Transaction) Insider: LOVE TED W (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

Waldstreicher Joanne (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Share Option (right to buy) 39,453 — —
Filing: Form 4 (Insider Transaction) Insider: Waldstreicher Joanne (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

DOBMEIER ERIC (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Share Option (right to buy) 39,453 — —
Filing: Form 4 (Insider Transaction) Insider: DOBMEIER ERIC (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

TETLOW SHARON (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Share Option (right to buy) 39,453 — —
Filing: Form 4 (Insider Transaction) Insider: TETLOW SHARON (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

GPCR insider Form 4 filed for equity award, exercise, or tax withholding

WELCH DANIEL G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Share Option (right to buy) 39,453 — —
Filing: Form 4 (Insider Transaction) Insider: WELCH DANIEL G (Director)
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Structure Therapeutics Inc. has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-21

GPCR Form 144 filed for proposed insider sale by BLAS COLL CRESPO (4,008 shares) ~$140.3K

BLAS COLL CRESPO filed a Form 144 with the SEC indicating intent to sell GPCR (Structure Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BLAS COLL CRESPO Shares: 4,008 Est. Value: $140.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-25

GPCR Form 144 filed for proposed insider sale by XICHEN LIN (35,512 shares) ~$1.71M

XICHEN LIN filed a Form 144 with the SEC indicating intent to sell GPCR (Structure Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: XICHEN LIN Shares: 35,512 Est. Value: $1.71M
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Structure Therapeutics Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-08

GPCR filed 8-K — material company event

Structure Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-06

GPCR filed 8-K — material company event

Structure Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-18

GPCR filed 8-K — material company event

Structure Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Structure Therapeutics Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

GPCR filed Quarterly Report (10-Q)

Structure Therapeutics Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Structure Therapeutics Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on GPCR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — GPCR SEC Filings

More Tools for GPCR

GPCR Full Stock Analysis GPCR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper GPCR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the GPCR stock analysis page.

GPCR Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer